VolitionRX Ltd VNRX 深 滬
交易中 04-01 10:53:33 美东时间
0.1927
-0.009
-4.60%
華盛通- 最 高0.1966
- 今 開0.1909
- 成交量 375.51万股
- 最 低 0.1902
- 昨 收 0.202
- 總市值 2612.34万
- 52周最高 0.94
- 市盈率 靜 --
- 換手率 2.77%
- 52周最低 0.17
- 委 比 -60.00%
- 總股本 1.36亿
- 歷史最高 9.28
- 量 比 0.63
- 振 幅 3.17%
- 歷史最低 0.17
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year. The
今天 04:47
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
VolitionRx To Highlight Use Of Its Nu.Q Cancer Assays In Management Of Lung Cancer Patients At European Lung Cancer Conference
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster
03-26 20:20
VolitionRx announces ELCC abstract on Nu.Q lung cancer blood test; study links preoperative H3K27Me3-nucleosome levels to recurrence-free and overall survival risk stratification
VolitionRx announces ELCC abstract on Nu.Q lung cancer blood test; study links preoperative H3K27Me3-nucleosome levels to recurrence-free and overall survival risk stratification Volition announced that an abstract on using its Nu.Q Cancer assays for lung cancer patient management was presented as a
03-26 20:17
Volition Announces Detection of Over 95% of Early-Stage Cancers
Blinded validation cohort achieves over 95% sensitivity for stage I & II cancers with 95% specificity Capture-Seq™ Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.,...
03-25 20:17
VolitionRx Achieves >99% Pure Tumor-Derived DNA Isolation With Novel ChIP-Seq Liquid Biopsy Technology, Advancing Early Cancer Detection
Targets $36 Billion TAM in Early Cancer Detection and MRD.Company in active discussions with global diagnostic leaders to accelerate commercialization.HENDERSON, Nev., March 18, 2026 /PRNewswire/ -- VolitionRx Limited
03-18 20:21
BRIEF-Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
BRIEF-Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna March 18 (Reuters) - VolitionRX Ltd VNRX.A : VOLITION REPORTS BREAKTHROUGH IN LIQUID BIOPSY: ACHIEVEMENT OF OVER 99% PURITY IN ISOLATING CANCER DNA Source text: ID:nPnc57dkxa Further company c
03-18 20:20
VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives
VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives Volition reported an updated manuscript describing a two-step method that generated sequencing datasets with more than 99% purity for circulating tumor-derived DNA from blood samples of cancer patie
03-18 20:17
VolitionRx Completes All Validation And Verification Of Chemiluminescent Immunoassay Version Of Nu.Q Vet Cancer Test With Fujifilm Vet Systems in Japan
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q®
03-06 21:12
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
HENDERSON, Nev., March 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation a...
03-06 21:10
